Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10483727 | 0.85 | ELANE (1.00) | ELANEPRTN3 | |
| SCHEMBL6337153 | 0.84 | ELANE (0.77) | ELANEPRTN3 | |
| SCHEMBL22369614 | 0.82 | ELANE (0.86) | ELANEPRTN3 | |
| SCHEMBL7183398 | 0.82 | ELANE (0.74) | ELANEPRTN3 | |
| SCHEMBL7183393 | 0.82 | ELANE (0.74) | ELANEPRTN3 | |
| SCHEMBL31531294 | 0.82 | ELANE (0.74) | ELANEPRTN3 | |
| SCHEMBL10483766 | 0.81 | ELANE (1.00) | ELANEPRTN3 | |
| SCHEMBL1279396 | 0.79 | MAPT (0.71) | ELANE | |
| SCHEMBL30259514 | 0.79 | ELANE (0.70) | ELANEPRTN3 | |
| SCHEMBL28598494 | 0.78 | ELANE (0.46) | ELANEPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9040692-A | — | — | None | — | — | JP | disclosed |
| US-20250091982-A1 | Pharmaceutical Composition, Methods of Use Thereof for Treating Cocaine Addiction, and Novel Use of Hausp K444R Point Mutant Mouse | PHARWAR BIOTECHNOLOGY, INC. PTE. LTD. (SG) | 2025-03-20 | — | — | US | disclosed |
| WO-2025056012-A1 | NEUTROPHIL ELASTASE INHIBITOR AND USE THEREOF | 上海壹迪生物技术有限公司 | 2025-03-20 | — | — | WO | disclosed |
| US-12018097-B2 | Non-chromatographic purification of macrocyclic peptides by a resin catch and release | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240051996-A1 | NON-CHROMATOGRAPHIC PURIFICATION OF MACROCYCLIC PEPTIDES BY A RESIN CATCH AND RELEASE | BRISTOL MYERS SQUIBB CO (US) | 2024-02-15 | — | — | US | disclosed |
| CN-116354855-B | Preparation method of cilansetrot sodium | 江苏百奥信康医药科技有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-116874396-A | Method for preparing high-purity cilansetron sodium | 南京福美瑞信科技有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116354855-A | Preparation method of cilansetrot sodium | 江苏百奥信康医药科技有限公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2023019499-A1 | ELASTASE INHIBITOR AND USE THEREOF IN DISEASE TREATMENT | 上海汇伦生物科技有限公司 | 2023-02-23 | — | — | WO | disclosed |
| CN-115703725-A | Elastase inhibitors and their use in the treatment of disease | 上海汇伦医药股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-9073833-B1 | Oxime-based compound, pharmaceutical composition containing the same and method for preparing the same | CHANG GUNG UNIVERSITY (TW) | 2015-07-07 | — | — | US | disclosed |
| US-6624193-B1 | Prophylactic and therapeutic medicament for ophthalmic diseases, especially ophthalmic inflammatory diseases and corneal ulcer, comprising as an active ingredient a compound represented by the formula phenylcarboxylate amidesulfonamide | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-23 | — | — | US | disclosed |
| EP-1213018-A1 | PREVENTIVE AND THERAPEUTIC AGENTS FOR EYE DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-12 | — | — | EP | disclosed |
| JP-H0940692-A | PRODUCTION OF GLYCINE DERIVATIVE | ONO PHARMACEUT CO LTD | 1997-02-10 | — | — | JP | disclosed |
| US-5359121-A | N-(o-(p-pivaloyloxybenzenesulfonylamino)benzoyl)glycine benzyl ester; elastase inhibitor; useful for treatment of emphysema, atherosclerosis, rheumatoid arthritis | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-10-25 | — | — | US | disclosed |
| US-5336681-A | Elastase inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-08-09 | — | — | US | disclosed |
| EP-0347168-B1 | DERIVATIVES OF P-SUBSTITUTED PHENYL ESTER OF PIVALIC ACID | ONO PHARMACEUTICAL CO (JP) | 1993-09-01 | — | — | EP | disclosed |
| EP-0539223-A1 | Glycine derivative monosodium salt tetrahydrate having an inhibitory effect on elastase | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-04-28 | — | — | EP | disclosed |
| US-5017610-A | Elastase inhibitor | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| EP-0347168-A1 | Derivatives of p-substituted phenyl ester of pivalic acid | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091982-A1 | Pharmaceutical Composition, Methods of Use Thereof for Treating Cocaine Addiction, and Novel Use of Hausp K444R Point Mutant Mouse | CES2, HDAC6, CHRNB4 | ELANE 973/4885PRTN3 843/4885 |
| US-20240051996-A1 | NON-CHROMATOGRAPHIC PURIFICATION OF MACROCYCLIC PEPTIDES BY A RESIN CATCH AND RELEASE | VIP, NPPA, ANPEP | ELANE 1356/4885PRTN3 1080/4885 |
| US-12018097-B2 | Non-chromatographic purification of macrocyclic peptides by a resin catch and release | VIP, NPR1, NPPA | ELANE 1661/4885PRTN3 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.